| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.4 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.043 | 0.4 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.17 | 0.4 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |